Advertisement
Canada markets closed
  • S&P/TSX

    21,708.44
    +52.39 (+0.24%)
     
  • S&P 500

    5,011.12
    -11.09 (-0.22%)
     
  • DOW

    37,775.38
    +22.07 (+0.06%)
     
  • CAD/USD

    0.7263
    -0.0001 (-0.01%)
     
  • CRUDE OIL

    82.63
    -0.10 (-0.12%)
     
  • Bitcoin CAD

    87,472.05
    +2,632.09 (+3.10%)
     
  • CMC Crypto 200

    1,310.42
    +424.88 (+47.98%)
     
  • GOLD FUTURES

    2,394.70
    -3.30 (-0.14%)
     
  • RUSSELL 2000

    1,942.96
    -4.99 (-0.26%)
     
  • 10-Yr Bond

    4.6470
    +0.0620 (+1.35%)
     
  • NASDAQ futures

    17,534.00
    -13.25 (-0.08%)
     
  • VOLATILITY

    18.00
    -0.21 (-1.15%)
     
  • FTSE

    7,877.05
    +29.06 (+0.37%)
     
  • NIKKEI 225

    38,079.70
    +117.90 (+0.31%)
     
  • CAD/EUR

    0.6823
    +0.0021 (+0.31%)
     

RDInvesting Provides Investors with Free In-Depth Equity Reports on ADBE, ENZ, IMAX and OPEN

Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at www.RDInvesting.com and get exclusive access to our numerous stock reports and market updates.

Adobe Systems Inc. (NASDAQ:ADBE - News) shares increased 2.81 percent to close at $59.72 a share Tuesday. The stock traded between $57.65 and $59.74 on volume of 3.59 million shares traded. Analysts at Sterne Agee have recently initiated coverage on the company with a "buy" rating and a price target of $70.00. Shares of Adobe Systems have gained approximately 55.0 percent in the past year.

Find out more about Adobe Systems including full access to the free equity report at:
www.RDInvesting.com/ADBE

Enzo Biochem, Inc. (NYSE:ENZ - News) shares increased 17.45 percent to close at $3.23 a share Tuesday. The stock traded between $2.73 and $3.34 on volume of 1.22 million shares traded. Analysts at Craig-Hallum have recently initiated coverage on the company with a "buy" rating and a price target of $5.50. Shares of Enzo Biochem have gained approximately 10.0 percent year-to-date.

ADVERTISEMENT

Find out more about Enzo Biochem including full access to the free equity report at:
www.RDInvesting.com/ENZ

IMAX Corporation (NYSE:IMAX - News)(TSX:IMX.TO - News) shares increased 0.27 percent to close at $26.26 a share Tuesday. The stock traded between $26.05 and $26.65 on volume of 584,412 shares traded. Analysts at CRT Capital have recently initiated coverage on the company with a "buy" rating and a price target of $40.00. Shares of IMAX have gained approximately 7.0 percent in the past year.

Find out more about IMAX including full access to the free equity report at:
www.RDInvesting.com/IMAX

OpenTable Inc. (NASDAQ:OPEN - News) shares increased 3.45 percent to close at $75.58 a share Tuesday. The stock traded between $74.57 and $76.68 on volume of 758,932 shares traded. Analysts at Citigroup have recently upgraded the company’s rating to "neutral" from "sell". Shares of OpenTable have fallen approximately 5.0 percent year-to-date.

Find out more about OpenTable including full access to the free equity report at:
www.RDInvesting.com/OPEN

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Research Driven Investing has no financial relationship with any company whose stock is mentioned in this release.

Contact:
Research Driven Investing
info@rdinvesting.com